Molecular Templates, Inc. (MTEM)
| Market Cap | 497.56M |
| Revenue (ttm) | 17.92M |
| Net Income (ttm) | -109.68M |
| Shares Out | 52.56M |
| EPS (ttm) | -2.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 15 |
| Last Price | $8.63 |
| Previous Close | $8.93 |
| Change ($) | -0.30 |
| Change (%) | -3.36% |
| Day's Open | 8.99 |
| Day's Range | 8.47 - 9.04 |
| Day's Volume | 463,357 |
| 52-Week Range | 7.51 - 16.41 |
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -282.14% and -89.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and develo...
Posters will feature data on MT-5111 (targeting HER2), MT-6402 (targeting PD-L1) and a novel CTLA-4-targeted ETB Posters will feature data on MT-5111 (targeting HER2), MT-6402 (targeting PD-L1) and a no...
The company is taking back rights to one drug candidate and discontinuing development of another.
Molecular Templates Inc (NASDAQ: MTEM) has decided to discontinue the development of MT-3724, its only first-generation engineered toxin bodies (ETB), and focus its resources on the development of next-...
Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma
AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and deve...
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.
Community Health Systems (NYSE: CYH) shares are trading higher after the company reported better-than-expected fourth-quarter sales results. Community Health Systems is the largest publicly owned hospit...
AUSTIN, Texas, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and developm...
Molecular Templates to receive $70 million upfront payment with potential for additional milestone and royalty payments on future sales Molecular Templates to receive $70 million upfront payment with po...
Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin ...
AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and develo...
AUSTIN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the disco...
AUSTIN, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...
AUSTIN, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the dis...
AUSTIN, Texas, July 20, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the dis...
Update Provided Phase I Study of MT-5111 in HER2-positive Cancers
Molecular Templates: Updates To Thesis, Pursuing Validated Targets With Unique MOA
AUSTIN, Texas, May 22, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the disc...
As of late, it has definitely been a great time to be an investor Molecular Templates
Milestone Triggers $10 Million Payment to Molecular Templates Milestone Triggers $10 Million Payment to Molecular Templates
Three Products Advancing in the Clinic with Additional Pipeline Growth to Come from Internal Research and Partnerships Three Products Advancing in the Clinic with Additional Pipeline Growth to Come from...
AUSTIN, Texas, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprie...
New drugs from these companies seek to enable more patients to receive cutting-edge cell and gene therapies.
AUSTIN, Texas, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and develo...
AUSTIN, Texas, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and develo...
AUSTIN, Texas, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s propriet...
Shares have risen by 20% since my initial article.
AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprie...
Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares have risen as a result of optimism regarding Takeda partnership and advancing ETB pipeline.
As of late, it has definitely been a great time to be an investor Molecular Templates.
Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About MTEM
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TA... [Read more...]
| Industry Biotechnology | |
| CEO Eric Poma | Employees 247 |
| Stock Exchange NASDAQ | Ticker Symbol MTEM |
Financial Performance
In 2020, MTEM's revenue was $18.85 million, a decrease of -15.38% compared to the previous year's $22.27 million. Losses were -$104.92 million, 51.1% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for MTEM stock is "Strong Buy." The 12-month stock price forecast is 15.38, which is an increase of 78.22% from the latest price.